Non-invasive Prenatal Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type, By Test Type, By Method, By Application, By End User, By Region & Competition, 2021-2031F

Description

The Global Non-invasive Prenatal Testing (NIPT) Market is projected to expand from USD 5.25 Billion in 2025 to USD 8.23 Billion by 2031, achieving a CAGR of 7.78%. NIPT serves as an advanced screening technique that examines cell-free fetal DNA found in maternal blood to identify chromosomal aneuploidies, including trisomy 21, 18, and 13. The primary catalysts for this market growth are the rising average maternal age worldwide and a distinct preference for safe, non-invasive alternatives to traditional invasive diagnostic procedures like amniocentesis. Furthermore, the continual enhancement of testing capabilities to cover a wider array of conditions supports increased adoption. For instance, the Association for Diagnostics & Laboratory Medicine reported in 2025 that research confirmed the expanded utility of these screenings by detecting Cytomegalovirus DNA in 2.1% of pregnancies, highlighting the potential for comprehensive fetal health assessments.

Market Overview
Forecast Period	2027-2031
Market Size 2025	USD 5.25 Billion
Market Size 2031	USD 8.23 Billion
CAGR 2026-2031	7.78%
Fastest Growing Segment	Harmony
Largest Market	North America

Despite these positive drivers, the market encounters a substantial obstacle regarding the high price of testing and variable reimbursement policies. This financial hurdle limits access for the general public, especially within developing nations and lower-income demographics, thereby preventing NIPT from becoming a universally implemented standard in routine prenatal care. Consequently, these economic barriers impede the global market's ability to reach full saturation.

Market Driver

Strategic partnerships and collaborations among leading market players are essential for broadening the global reach and capabilities of diagnostic providers in the NIPT sector. By acquiring regional laboratories and forming alliances, major companies are consolidating the market to strengthen distribution networks and incorporate specialized testing technologies into their portfolios. This consolidation facilitates the efficient delivery of prenatal screening services to diverse patient populations and accelerates the availability of comprehensive women's health solutions. For example, Labcorp announced in its 'Fourth Quarter and Full Year 2024 Results' in February 2025 that it completed 10 transactions throughout 2024 to solidify its position as a trusted partner to health systems, significantly reinforcing its presence in high-growth areas such as women's health.

The rising average maternal age globally serves as a primary catalyst for the sustained demand for chromosomal aneuploidy screening. As delayed childbearing trends continue due to changing socio-economic factors, the increased clinical risk of chromosomal abnormalities in older mothers necessitates reliable, non-invasive fetal health evaluations. According to the CDC's 'Births: Provisional Data for 2024' report released in April 2025, the birth rate for women aged 40-44 rose by 2% in 2024, highlighting this significant demographic shift. This increase in higher-risk pregnancies correlates directly with higher utilization rates of prenatal diagnostics; Myriad Genetics reported in February 2025 that prenatal testing revenue grew 12% year-over-year, reflecting the strong uptake of these essential screenings driven by demographic pressures.

Market Challenge

The Global Non-invasive Prenatal Testing (NIPT) Market is significantly constrained by high testing costs and the absence of consistent reimbursement policies across various regions and insurance providers. Although NIPT is acknowledged for its accuracy, substantial out-of-pocket expenses create a severe barrier to entry for a large segment of the population, particularly in developing economies and among average-risk pregnancies where insurance coverage is frequently denied or limited. This financial disparity prevents the test from becoming a universal standard of care, effectively categorizing it as a premium service rather than a routine medical procedure available to all expectant mothers.

As a result, market penetration remains uneven, with growth heavily concentrated in demographics that benefit from full financial coverage. In 2025, the German Medical Association highlighted this discrepancy, revealing that only approximately 25% of pregnant women under the age of 26 accessed NIPT services due to funding limitations, compared to significantly higher adoption rates in age groups with established reimbursement coverage. This divide illustrates how economic factors and inconsistent payer policies directly restrict the scalable expansion of the NIPT market, limiting its potential to reach saturation in the broader prenatal care sector.

Market Trends

The expansion of testing coverage to include average-risk pregnancies marks a fundamental shift in the market, transitioning the consumer base from exclusively high-risk cases to the broader general population. This evolution differs from demographic drivers as it relies on the normalization of screening as a standard routine for all expectant mothers regardless of age, supported by increasing clinical validation for younger demographics. The uptake in this wider segment is rapidly accelerating test volumes, creating a new primary engine for industry expansion. Evidencing this mass-market adoption, Natera reported in its 'Third Quarter 2025 Financial Results' in November 2025 that the company processed approximately 893,600 tests, a 15.2% increase year-over-year, driven largely by the robust penetration of these screenings into broader patient categories.

Concurrently, the industry is advancing through the development of comprehensive multi-gene panel testing, which extends diagnostic capabilities beyond standard aneuploidy detection. Manufacturers are innovating assays that identify specific single-gene disorders and rare conditions previously undetectable via non-invasive methods, thereby addressing the clinical need for higher diagnostic yield in early pregnancy. This technological evolution enables the screening of complex inherited conditions, providing deeper genetic insights that facilitate earlier interventions. Highlighting this advancement, Natera announced in October 2025 the expansion of its single-gene testing panel to cover 20 genes, significantly enhancing its capability to detect challenging homozygous mutations and severe early-onset disorders.

Key Market Players

YOURGENE HEALTH Plc
Illumina, Inc.
Natera, Inc.
F.Hoffman La Roche Ltd.
Perkin Elmer Inc.
Laboratory Corporation of America Holdings
Eurofins LifeCodex GmbH
Progenity, Inc.
Genesis Genetics
Quest Diagnostics Incorporated

Report Scope

In this report, the Global Non-invasive Prenatal Testing (NIPT) Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Non-invasive Prenatal Testing (NIPT) Market, By Product Type

Consumables
Instruments

Non-invasive Prenatal Testing (NIPT) Market, By Test Type

Materni 21
Harmony
Panaroma
Verifi
NIFTY
Others

Non-invasive Prenatal Testing (NIPT) Market, By Method

Ultrasound Detection
Biochemical Screening Testing
Cell-Free DNA Maternal Plasma Tests
Fetal Cells in Maternal Blood Tests
Others

Non-invasive Prenatal Testing (NIPT) Market, By Application

Trisomy
Microdeletion Syndrome
Others

Non-invasive Prenatal Testing (NIPT) Market, By End User

Diagnostic Laboratories
Hospitals
Others

Non-invasive Prenatal Testing (NIPT) Market, By Region

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Non-invasive Prenatal Testing (NIPT) Market.

Available Customizations:

Global Non-invasive Prenatal Testing (NIPT) Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Non-invasive Prenatal Testing (NIPT) Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Product Type (Consumables, Instruments)
- 5.2.2. By Test Type (Materni 21, Harmony, Panaroma, Verifi, NIFTY, Others)
- 5.2.3. By Method (Ultrasound Detection, Biochemical Screening Testing, Cell-Free DNA Maternal Plasma Tests, Fetal Cells in Maternal Blood Tests, Others)
- 5.2.4. By Application (Trisomy, Microdeletion Syndrome, Others)
- 5.2.5. By End User (Diagnostic Laboratories, Hospitals, Others)
- 5.2.6. By Region
- 5.2.7. By Company (2025)
5.3. Market Map

6. North America Non-invasive Prenatal Testing (NIPT) Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Product Type
- 6.2.2. By Test Type
- 6.2.3. By Method
- 6.2.4. By Application
- 6.2.5. By End User
- 6.2.6. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Non-invasive Prenatal Testing (NIPT) Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Product Type
    - 6.3.1.2.2. By Test Type
    - 6.3.1.2.3. By Method
    - 6.3.1.2.4. By Application
    - 6.3.1.2.5. By End User
- 6.3.2. Canada Non-invasive Prenatal Testing (NIPT) Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Product Type
    - 6.3.2.2.2. By Test Type
    - 6.3.2.2.3. By Method
    - 6.3.2.2.4. By Application
    - 6.3.2.2.5. By End User
- 6.3.3. Mexico Non-invasive Prenatal Testing (NIPT) Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Product Type
    - 6.3.3.2.2. By Test Type
    - 6.3.3.2.3. By Method
    - 6.3.3.2.4. By Application
    - 6.3.3.2.5. By End User

7. Europe Non-invasive Prenatal Testing (NIPT) Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Product Type
- 7.2.2. By Test Type
- 7.2.3. By Method
- 7.2.4. By Application
- 7.2.5. By End User
- 7.2.6. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Non-invasive Prenatal Testing (NIPT) Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Product Type
    - 7.3.1.2.2. By Test Type
    - 7.3.1.2.3. By Method
    - 7.3.1.2.4. By Application
    - 7.3.1.2.5. By End User
- 7.3.2. France Non-invasive Prenatal Testing (NIPT) Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Product Type
    - 7.3.2.2.2. By Test Type
    - 7.3.2.2.3. By Method
    - 7.3.2.2.4. By Application
    - 7.3.2.2.5. By End User
- 7.3.3. United Kingdom Non-invasive Prenatal Testing (NIPT) Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Product Type
    - 7.3.3.2.2. By Test Type
    - 7.3.3.2.3. By Method
    - 7.3.3.2.4. By Application
    - 7.3.3.2.5. By End User
- 7.3.4. Italy Non-invasive Prenatal Testing (NIPT) Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Product Type
    - 7.3.4.2.2. By Test Type
    - 7.3.4.2.3. By Method
    - 7.3.4.2.4. By Application
    - 7.3.4.2.5. By End User
- 7.3.5. Spain Non-invasive Prenatal Testing (NIPT) Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Product Type
    - 7.3.5.2.2. By Test Type
    - 7.3.5.2.3. By Method
    - 7.3.5.2.4. By Application
    - 7.3.5.2.5. By End User

8. Asia Pacific Non-invasive Prenatal Testing (NIPT) Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Product Type
- 8.2.2. By Test Type
- 8.2.3. By Method
- 8.2.4. By Application
- 8.2.5. By End User
- 8.2.6. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China Non-invasive Prenatal Testing (NIPT) Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Product Type
    - 8.3.1.2.2. By Test Type
    - 8.3.1.2.3. By Method
    - 8.3.1.2.4. By Application
    - 8.3.1.2.5. By End User
- 8.3.2. India Non-invasive Prenatal Testing (NIPT) Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Product Type
    - 8.3.2.2.2. By Test Type
    - 8.3.2.2.3. By Method
    - 8.3.2.2.4. By Application
    - 8.3.2.2.5. By End User
- 8.3.3. Japan Non-invasive Prenatal Testing (NIPT) Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Product Type
    - 8.3.3.2.2. By Test Type
    - 8.3.3.2.3. By Method
    - 8.3.3.2.4. By Application
    - 8.3.3.2.5. By End User
- 8.3.4. South Korea Non-invasive Prenatal Testing (NIPT) Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Product Type
    - 8.3.4.2.2. By Test Type
    - 8.3.4.2.3. By Method
    - 8.3.4.2.4. By Application
    - 8.3.4.2.5. By End User
- 8.3.5. Australia Non-invasive Prenatal Testing (NIPT) Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Product Type
    - 8.3.5.2.2. By Test Type
    - 8.3.5.2.3. By Method
    - 8.3.5.2.4. By Application
    - 8.3.5.2.5. By End User

9. Middle East & Africa Non-invasive Prenatal Testing (NIPT) Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Product Type
- 9.2.2. By Test Type
- 9.2.3. By Method
- 9.2.4. By Application
- 9.2.5. By End User
- 9.2.6. By Country
9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia Non-invasive Prenatal Testing (NIPT) Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Product Type
    - 9.3.1.2.2. By Test Type
    - 9.3.1.2.3. By Method
    - 9.3.1.2.4. By Application
    - 9.3.1.2.5. By End User
- 9.3.2. UAE Non-invasive Prenatal Testing (NIPT) Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Product Type
    - 9.3.2.2.2. By Test Type
    - 9.3.2.2.3. By Method
    - 9.3.2.2.4. By Application
    - 9.3.2.2.5. By End User
- 9.3.3. South Africa Non-invasive Prenatal Testing (NIPT) Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Product Type
    - 9.3.3.2.2. By Test Type
    - 9.3.3.2.3. By Method
    - 9.3.3.2.4. By Application
    - 9.3.3.2.5. By End User

10. South America Non-invasive Prenatal Testing (NIPT) Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Product Type
- 10.2.2. By Test Type
- 10.2.3. By Method
- 10.2.4. By Application
- 10.2.5. By End User
- 10.2.6. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil Non-invasive Prenatal Testing (NIPT) Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Product Type
    - 10.3.1.2.2. By Test Type
    - 10.3.1.2.3. By Method
    - 10.3.1.2.4. By Application
    - 10.3.1.2.5. By End User
- 10.3.2. Colombia Non-invasive Prenatal Testing (NIPT) Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Product Type
    - 10.3.2.2.2. By Test Type
    - 10.3.2.2.3. By Method
    - 10.3.2.2.4. By Application
    - 10.3.2.2.5. By End User
- 10.3.3. Argentina Non-invasive Prenatal Testing (NIPT) Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Product Type
    - 10.3.3.2.2. By Test Type
    - 10.3.3.2.3. By Method
    - 10.3.3.2.4. By Application
    - 10.3.3.2.5. By End User

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Global Non-invasive Prenatal Testing (NIPT) Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. YOURGENE HEALTH Plc
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
15.2. Illumina, Inc.
15.3. Natera, Inc.
15.4. F.Hoffman La Roche Ltd.
15.5. Perkin Elmer Inc.
15.6. Laboratory Corporation of America Holdings
15.7. Eurofins LifeCodex GmbH
15.8. Progenity, Inc.
15.9. Genesis Genetics
15.10. Quest Diagnostics Incorporated